Overview of Opdivo

Quick Facts

Property	Description
Active Ingredient	Nivolumab
Form	Solution for Intravenous Infusion, Solution for Subcutaneous Injection (OPDIVO Qvantig)
Pharmacological Class	Immune Checkpoint Inhibitor (Anti-PD-1 Monoclonal Antibody)
General Purpose	Restores the immune system’s ability to recognize and target abnormal cells
Origin	Biological/Biotechnological (Fully human monoclonal antibody)

Opdivo is a prescription medicine whose active ingredient is nivolumab, classified as a programmed death-1 (PD-1) blocking antibody. This medication represents a specialized targeted immunotherapy, distinct from traditional cytotoxic chemotherapy, as it functions by modulating the body's protective immune response.

Opdivo: A Monoclonal Antibody and Targeted Immunotherapy

Opdivo (nivolumab) is a biological medicine that falls under the pharmacological class of immune checkpoint inhibitors, a type of targeted immunotherapy supported by extensive clinical evidence. The active substance is a fully human monoclonal antibody, an engineered protein designed to bind with high specificity to a single biological target. Nivolumab works by increasing the ability of the immune system to kill abnormal cells. Its manufacturing process involves recombinant DNA technology using specialized mammalian cells, underscoring its biotechnological origin. Nivolumab is clinically recognized for its role in treating advanced disease states by fundamentally enhancing immune surveillance.

General Purpose of PD-1 Pathway Blockade

The overarching therapeutic purpose of nivolumab is to enhance the immune system's native ability to recognize and counteract disease by removing a central inhibitory signal. Nivolumab acts as an anti-PD-1 agent by selectively binding to the PD-1 receptor found on T-cells. This binding action prevents the PD-1 receptor from being activated by inhibitory ligands, which are often used by abnormal cells to evade detection. This mechanism successfully releases the immune cells from this pathological suppression, restoring a potent anti-disease immune response. This approach has been found to promote durable, long-term immune-mediated control in patient populations, differentiating it from therapies that offer only temporary symptomatic relief.

Available Forms: Intravenous Solution and Subcutaneous Alternative

The primary preparation of nivolumab is a clear-to-opalescent aqueous solution used to prepare a concentrate for intravenous infusion. This administration method is typical for many antibody-based therapies. Opdivo distinguishes itself by also having an alternative formulation, OPDIVO Qvantig, which contains nivolumab combined with the enzyme hyaluronidase. This specific combination permits the medicine to be delivered via subcutaneous injection (under the skin), offering a delivery option for patients where an intravenous infusion may be less practical.

Regulatory References

What side effects are possible with Opdivo?

The official safety profile of Opdivo (nivolumab) is primarily characterized by the risk of severe and potentially fatal immune-mediated adverse reactions. These effects stem from the medication's intended action of activating the immune system, which can result in inflammation across various organ systems. These immune-mediated reactions can occur during treatment or even after discontinuation of the medicine, which is an important pattern noted in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by frequency in official labels. When used as a single agent, the most common adverse reactions (occurring in ge 20% of patients) include fatigue, rash, musculoskeletal pain, pruritus (itching), diarrhea, and nausea. These effects are generally categorized under the Very Common frequency classification.

System-Organ Class (SOC)	Examples of Serious Adverse Reactions
Respiratory	Immune-mediated pneumonitis (lung inflammation)
Gastrointestinal	Immune-mediated colitis (colon inflammation)
Endocrine	Immune-mediated endocrinopathies (e.g., adrenal insufficiency, hypophysitis, thyroid disorders)
Hepatic & Renal	Immune-mediated hepatitis and nephritis/renal dysfunction

Safety Constraints and Special Populations

Official labeling includes specific constraints regarding use in certain contexts. The use of nivolumab in combination with a thalidomide analogue and dexamethasone for multiple myeloma is not recommended outside of controlled clinical trials due to increased mortality. Furthermore, treatment is associated with the risk of fetal harm, and official documents advise that women discontinue breastfeeding during treatment. The risk of fatal complications, including Graft-Versus-Host-Disease (GVHD), is documented for patients who receive allogeneic Hematopoietic Stem Cell Transplantation (HSCT) before or after nivolumab therapy.

Overdose and Emergency Response

Opdivo Overdose and When to Seek Help

The official regulatory profile for nivolumab overdose is defined by the absence of specific clinical experience. According to the prescribing information, no cases of overdose were formally reported during the clinical trials, meaning specific symptoms or clinical manifestations directly attributed to an overdose event are not detailed in the official labeling. The overdose findings are thus constrained by this context of no reported cases.

Required Emergency Actions and Management

In the event of a suspected overdose of Opdivo, it is mandated that patients must seek immediate medical attention and contact emergency services for necessary supervision and care. The primary regulatory instruction is for the patient to be placed under close monitoring for any general signs or symptoms of adverse reactions. Furthermore, the official labeling explicitly requires that appropriate symptomatic treatment must be instituted immediately by a healthcare professional.

Antidote and Procedural Notes

No specific pharmacological antidote for nivolumab overdose is specified or documented in the official prescribing information. Consequently, management is entirely procedural and supportive. The entire emergency response is focused on intensive observation and the immediate provision of supportive care, emphasizing the necessity of immediate medical supervision in any suspected excessive exposure scenario as defined by the regulatory authorities.

Therapeutic Uses of Opdivo

What Opdivo Treats: Main Uses and Benefits

This medication is commonly used across numerous conditions, including metastatic melanoma, advanced non-small cell lung cancer, renal cell carcinoma, and several gastrointestinal cancers. This medication is relevant in situations where patients experience these conditions. The medication is applied when conditions present with systemic or localized discomfort due to the extent of the disease. The primary focus is managing symptoms that create noticeable physiological strain, which helps ease the overall symptom load and supports general well-being during symptomatic phases.

The medication is relevant in contexts marked by increased discomfort or tension, such as in clinical settings where the patient's condition has progressed despite having previously received standard treatments. This approach is commonly used to help with challenging symptomatic phases, assisting with maintaining functional stability and is applied during phases of increased distress or discomfort. In high-risk scenarios, it is applied when appropriate in the adjuvant setting to help address the risk of the condition returning. This use is applied across domains where additional symptomatic support is needed to address the risk of recurrent or episodic manifestations.

Quick Fact: Relief for Cancer-Related Symptom Clusters
Symptom Management Focus	Supports easing the overall symptom load linked to advanced, active tumor growth and symptoms that create noticeable physiological strain.
Clinical Contexts	Used in advanced/metastatic disease and as adjuvant therapy in conditions involving recurrent or episodic manifestations.
Patient Benefit	Contributes to improved comfort during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

The eligibility for using Opdivo (nivolumab) is strictly defined by regulatory bodies, addressing specific populations and pre-existing conditions.

Eligibility and Non-Eligibility Summary

Population Group	Official Regulatory Status
Pediatric Use	Approved for patients 12 years and older for certain indications (e.g., MSI-H/dMMR colorectal cancer, melanoma). Safety/efficacy not established for most indications in children younger than 12.
Pregnancy	Not recommended. Can cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for a specified period (e.g., 5 months) after the last dose.
Breastfeeding	Not recommended. Women should not breastfeed during treatment and for a specified period (e.g., 5 months) after the last dose due to potential serious adverse reactions in the infant.
Multiple Myeloma	Not recommended for use in combination with a thalidomide analogue plus dexamethasone outside of controlled clinical trials, due to documented increased mortality.
Severe Organ Impairment	Use is limited by insufficient data in patients with severe renal impairment or moderate or severe hepatic impairment.
Prior Transplant	Use in patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT) requires careful monitoring due to risk of serious complications.

Contraindications are not listed for nivolumab monotherapy in the core prescribing information, but permanent discontinuation is required following severe, life-threatening, or recurring immune-mediated adverse reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for nivolumab (Opdivo) is predominantly defined by pharmacodynamic restrictions and specific contraindicated combinations, which is consistent with its classification as an immune-modulating monoclonal antibody.

Documented Pharmacodynamic and Immunologic Interactions

Classification Type	Interacting Agent or Category	Regulatory Restriction
Pharmacodynamic Antagonism	Systemic Immunosuppressive Drugs (e.g., Corticosteroids at immunosuppressive doses)	Co-administration is not recommended at treatment initiation as it risks interfering with the drug's therapeutic immune effect.
Pharmacodynamic Reinforcement	Ipilimumab (Anti-CTLA-4 Antibody)	Leads to a higher frequency and severity of immune-mediated adverse reactions; requires mandatory simultaneous withholding if one agent is interrupted due to toxicity.
Contraindicated Combination	Live Attenuated Vaccines	Co-administration is not recommended due to the potential risk of severe or disseminated infection.
Specific Combination Use	Thalidomide Analogue + Dexamethasone (in Multiple Myeloma)	Use Not Recommended based on reported increased mortality in this specific disease context.

Pharmacokinetic and General Considerations

The regulatory documents state that no clinically significant pharmacokinetic interactions are expected with medicines that inhibit or induce Cytochrome P450 (CYP) enzymes or drug transporters. Nivolumab is cleared primarily by catabolism, making it generally unaffected by these metabolic pathways. Additionally, for patients with severe hepatic impairment, specific dosage adjustment recommendations are not available, and caution is required.

Mechanism of Action

The mechanism of Opdivo (nivolumab) centers on modulating the body's protective immune system by targeting a critical inhibitory pathway on T-cells. The drug functions as an antagonist by binding directly to the Programmed Death-1 ( PD-1) receptor found on T-lymphocytes. This molecular block prevents the receptor from engaging its ligand, PD-L1, thereby interrupting the negative regulatory cascade that induces T-cell exhaustion. Interrupting this negative cascade restores the T-cells' capacity for proliferation, cytokine production, and cytotoxic effector function. This action re-establishes a T-cell-mediated immune response that recognizes and engages cells expressing PD-L1. For the subcutaneous formulation, the co-administered enzyme hyaluronidase temporarily degrades hyaluronan in the subcutaneous extracellular matrix. This physical alteration facilitates the dispersal and subsequent absorption of the large nivolumab antibody into the systemic circulation. The effectiveness of the blockade is functionally constrained by PD-L1 expression, T-cell presence, and the potential activation of alternative immunosuppressive pathways.

Dosage and Administration Information

How to Use Opdivo

Opdivo (nivolumab) is administered as a planned, intermittent treatment according to a specific schedule. The medicine is primarily given through a cyclic pattern either as a single agent or as part of a combination regimen.

Administration Routes and Standard Dosing

The most common route of administration is Intravenous (IV) Infusion, utilizing the 10 mg/mL concentrate. An alternative route is Subcutaneous (SC) Injection, which uses a co-formulation (OPDIVO Qvantig) containing nivolumab and hyaluronidase.

Standard fixed doses for adults typically involve either 240 mg IV every 2 weeks or 480 mg IV every 4 weeks. The labeled SC regimen uses a higher fixed dose of 600 mg every 2 weeks or 1,200 mg every 4 weeks. For certain combination therapies and for pediatric patients weighing less than 40 kg, a weight-based dose is applied.

Procedural Instructions and Course Duration

Prior to IV delivery, the concentrate must be diluted with 0.9% Sodium Chloride or 5% Dextrose Injection to a final concentration between 1 mg/mL and 10 mg/mL. The infusion must be delivered over a specific time, usually 30 minutes or 60 minutes depending on the regimen, and requires an in-line filter during administration. The SC injection is administered over a shorter period of 3 to 5 minutes.

Regarding duration, treatment for most advanced conditions continues until disease progression or unacceptable toxicity. However, in the adjuvant setting for specific conditions, therapy is limited to a fixed duration, such as up to one year.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Opdivo

Evidence for Advanced and Adjuvant Melanoma

This section will summarize the structure of Phase 3 Randomized Controlled Trials (RCTs) and related studies that explored Opdivo's use in advanced melanoma that cannot be surgically removed (metastatic) and its evaluation after surgery to study recurrence risk (adjuvant setting).

Study Designs and Primary Measures in Melanoma

Research has explored the use of Opdivo in individuals with melanoma that is considered advanced or has spread (metastatic). Studies often involved Randomized Controlled Trials (RCTs), where people were assigned by chance to receive either Opdivo (alone or in combination with another agent like ipilimumab) or a standard treatment such as chemotherapy. The primary measures monitored included assessments of longevity (Overall Survival or OS) and the proportion of patients whose tumors shrank or disappeared (Objective Response Rate or ORR).

For patients whose melanoma was completely removed by surgery but who are at high risk of recurrence (adjuvant setting), other major RCTs were conducted. These studies compared Opdivo to either an active competitor or to an inactive substance (placebo). Here, research monitored the time without the cancer returning (Disease-Free Survival or DFS) as the main outcome, along with the eventual Overall Survival. Studies so far describe patterns where recurrence-free survival measurements were observed in the Opdivo arm compared to the comparator arm.

What remains uncertain for the treatment of advanced melanoma is the optimal timing and sequence for using Opdivo alone versus using it in combination with other agents, which continues to be an area of research. Additionally, while long-term follow-up data has been gathered for several years, the complete picture of long-term outcomes and durability of response is still being established through continued observation.

Evidence for Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC)

This section will outline the structure of regulatory-supported research for two major solid tumor indications: Advanced NSCLC and Advanced RCC. It will cover studies that explored Opdivo's use alone (monotherapy) and in combination with other treatments.

Study Designs and Primary Measures in Lung Cancer

Research on Non-Small Cell Lung Cancer (NSCLC) has explored Opdivo in multiple scenarios. In patients whose cancer progressed after platinum-based chemotherapy, RCTs compared Opdivo alone against standard chemotherapy (like docetaxel). In the initial treatment (first-line) setting, studies monitored Opdivo in combination with other therapies (like chemotherapy and/or ipilimumab) against chemotherapy alone. Research also examined Opdivo combined with chemotherapy before surgery (neoadjuvant setting) to examine the extent of tumor size change prior to removal. Key outcomes monitored in these trials included Overall Survival (OS), Progression-Free Survival (PFS), and the extent of cancer reduction in the removed tissue (Pathological Complete Response or pCR).

The findings from metastatic studies generally describe Overall Survival measurements observed in the Opdivo arms compared to the chemotherapy comparator arms in previously treated patients. Neoadjuvant studies reported Pathological Complete Response (pCR) measurements when Opdivo was combined with chemotherapy. The research, however, provides limited insight into outcomes for patients with certain genetic markers (EGFR or ALK) whose disease has not yet progressed on targeted therapies.

Study Designs and Primary Measures in Kidney Cancer

For Advanced Renal Cell Carcinoma (RCC), Opdivo was evaluated in RCTs both as a single agent for patients whose disease progressed after prior therapy, and in combination with other drugs (like ipilimumab or cabozantinib) as an initial treatment. These studies primarily monitored Overall Survival (OS) and Progression-Free Survival (PFS).

In the initial treatment setting, first-line combination trials described Overall Survival measurements observed in the combination arms compared to the standard agent (sunitinib) for patients categorized with intermediate or poor prognostic risk factors. However, the optimal choice among the different approved combination regimens (e.g., nivolumab/ipilimumab versus nivolumab/cabozantinib) requires further comparative research. In the second-line monotherapy setting, trials reported various Overall Survival and Progression-Free Survival (PFS) measurements compared to the active comparator.

Evidence for Other Advanced Cancers

This section will provide a brief overview of the research framework for other conditions where Opdivo is evaluated, including Classical Hodgkin Lymphoma (cHL), Head and Neck Squamous Cell Carcinoma (SCCHN), and specific Gastrointestinal Cancers (e.g., Esophageal/GEJ Adenocarcinoma, MSI-H/dMMR Colorectal Cancer).

Research for Classical Hodgkin Lymphoma (cHL) that has relapsed or progressed has relied mainly on non-randomized, single-arm studies that focused on the proportion of patients whose tumors shrank (ORR) and the Duration of Response (DoR). Because these were not comparative trials, the research structure provides limited comparative context with other treatment options. For Head and Neck Squamous Cell Carcinoma (SCCHN), RCTs compared Opdivo against chemotherapy in patients whose cancer progressed after prior platinum-based therapy, with results describing patterns related to Overall Survival.

In certain Gastrointestinal Cancers, research has focused on specific populations. For Esophageal/Gastroesophageal Junction (GEJ) cancer, studies explored Opdivo was studied in the adjuvant setting (after surgery) for patients who still had residual disease following initial chemoradiotherapy, monitoring Disease-Free Survival (DFS). The main trial (CheckMate 577) reported Disease-Free Survival measurements observed in the Opdivo arm compared to the placebo arm. Similarly, for metastatic Colorectal Cancer (CRC), research focused on a specific patient group whose tumors exhibited a particular biomarker (MSI-H/dMMR), with studies observing responses over defined time intervals.

Long-Term Studies and Durability of Response

This block will summarize what the research indicates about the durability of responses measured in the clinical trials, including the extent of long-term follow-up data available for survival and recurrence risk, and the limitations related to extended-duration information.

Many of the initial regulatory approvals for Opdivo were based on measurements taken relatively early in the clinical development process, often using surrogate endpoints like tumor shrinkage (ORR) or time without progression (PFS). Research is ongoing, and long-term data for assessments of longevity (OS) and durability of response (DoR) is continually collected in most major studies. This extended data contributes to the broader evidence landscape regarding whether the patterns observed early on were sustained. However, the full characterization of late or long-term effects are not fully established and require continued post-marketing and observational research.

Evidence in Special Populations

This section will outline the research that has specifically evaluated the use of Opdivo in certain patient groups, such as adolescents (in melanoma), patients stratified by biomarker status (e.g., PD-L1 expression, MSI-H/dMMR), and other subgroups defined by the trials.

Studies have included adolescents ( ge 12 years old) for specific indications, such as melanoma. Furthermore, research has closely examined outcomes based on biomarker status, such as the expression level of the PD-L1 protein or the presence of specific genetic features like MSI-H/dMMR in colorectal cancer. In several indications, findings indicate that patterns of response may differ between patients depending on these biomarker measurements. Therefore, the results apply only to the populations studied and defined by the specific inclusion criteria of those research protocols. Data for certain groups, such as pregnant women, remain limited.

What is Still Uncertain About Opdivo Research

This final section will synthesize the main evidence gaps and unanswered questions documented in authoritative sources, such as areas where limited comparative data exists, where only surrogate endpoints were initially used, or where the role of optimal sequencing requires further investigation.

While the evidence landscape is extensive, certain aspects of Opdivo's use remain subject to ongoing research. In some cases, initial approvals were based on evidence provided by single-arm trials or on surrogate endpoints (like ORR) where full long-term Overall Survival data was not yet mature. This means research is ongoing, and the extent of late-stage effects of the treatment in some contexts is still being fully established. Additionally, comparative evidence is lacking for certain approved regimens, making it difficult for research to suggest which of the various available combination therapies might be optimal in a given situation. Furthermore, the precise role of Opdivo in patients with rare disease subtypes or specific combinations of other health issues (comorbidities) is not fully characterized, as these groups are often excluded from or underrepresented in major clinical trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Opdivo (FAQ)

Q: Does Opdivo cause hair loss (alopecia)?

A: According to official product information, hair loss (alopecia) is not listed among the most common adverse reactions (those occurring in 10% or more of patients) when Opdivo is used alone or in its main combination therapies. The full range of possible side effects is detailed in the complete official prescribing information.

Q: What should I do if my IV infusion site becomes painful or swollen?

A: Regulatory documents include warnings about the risk of infusion reactions, which can involve symptoms such as rash, flushing, or swelling at the IV site. Official guidance emphasizes the importance of reporting any such symptoms to the healthcare team. These types of reactions typically lead to careful monitoring and management by a healthcare professional.

Q: What is the longest course duration for Opdivo treatment?

A: The duration of Opdivo treatment varies depending on the specific condition being treated. For certain advanced cancers, treatment may continue until the cancer progresses or until unacceptable side effects occur. In other contexts, particularly in the adjuvant setting (treatment after surgery), the duration is fixed, for example, lasting up to one or two years.

Q: Is it safe to take Opdivo if I am pregnant or planning to breastfeed?

A: Official regulatory information states that Opdivo is not recommended during pregnancy because of the potential for it to cause fetal harm. Additionally, women are advised not to breastfeed during treatment and for a specified period after the final dose. Regulatory guidelines recommend that females of reproductive potential discuss the need for effective contraception with their healthcare provider during and for a specified period after treatment.

Q: What type of cancers does Opdivo treat?

A: Opdivo is approved by regulatory bodies to treat several types of advanced and metastatic cancers. These indications include various forms of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and certain gastrointestinal, head and neck, and blood cancers like classical Hodgkin lymphoma (cHL).

How should Opdivo be stored and disposed of?

How to Store and Dispose of Opdivo (nivolumab)

The officially documented storage and disposal requirements for Opdivo are necessary to maintain the product's stability and integrity.

Storage Requirements

Product State	Temperature Requirement	Handling/Protection Rule
Unopened Vial	Store under refrigeration at 2 C to 8 C (36 F to 46 F).	Store in the original carton to protect from light; Do not freeze and Do not shake.
Diluted Infusion	Stable for up to 7 days when refrigerated, or up to 8 hours at room temperature.	Must be protected from light when refrigerated.

Child Safety and Disposal

The medicine must be kept out of the reach and sight of children at all times. Opdivo vials are for single-use only. Any partially used vials, empty vials, or diluted solution that exceeds the stated stability limits must be discarded according to local pharmaceutical waste procedures.

Opdivo